Monday January 17th, 2022 4:43PM
12:00AM ( 16 hours ago ) Weather Alert
3:00PM ( 2 days ago ) Weather Alert

Pfizer says COVID-19 pill cut hospital, death risk by 90%

By The Associated Press
Related Articles
  Contact Editor

WASHINGTON (AP) — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus.

Currently most COVID-19 treatments require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.

Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.

Since the beginning of the pandemic last year, researchers worldwide have been racing to find a pill to treat COVID-19 that can be taken at home to ease symptoms, speed recovery and keep people out of the hospital.

Having pills to treat early COVID-19 “would be a very important advance," said Dr. John Mellors, chief of infectious diseases at the University of Pittsburgh, who was not involved in the Pfizer study.

“If someone developed symptoms and tested positive we could call in a prescription to the local pharmacy as we do for many, many infectious diseases," he said.

On Friday, Pfizer released preliminary results of its study of 775 adults. Patients who received the company's drug along with another antiviral shortly after showing COVID-19 symptoms had an 89% reduction in their combined rate of hospitalization or death after a month, compared to patients taking a dummy pill. Fewer than 1% of patients taking the drug needed to be hospitalized and no one died. In the comparison group, 7% were hospitalized and there were seven deaths.

"We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer, in an interview.

Study participants were unvaccinated, with mild-to-moderate COVID-19, and were considered high risk for hospitalization due to health problems like obesity, diabetes or heart disease. Treatment began within three to five days of initial symptoms, and lasted for five days. Patients who received the drug earlier showed slightly better results, underscoring the need for speedy testing and treatment.

Pfizer reported few details on side effects but said rates of problems were similar between the groups at about 20%.

An independent group of medical experts monitoring the trial recommended stopping it early, standard procedure when interim results show such a clear benefit. The data have not yet been published for outside review, the normal process for vetting new medical research.

Top U.S. health officials continue to stress that vaccination will remain the best way to protect against infection. But with tens of millions of adults still unvaccinated — and many more globally — effective, easy-to-use treatments will be critical to curbing future waves of infections.

The FDA has set a public meeting later this month to review Merck’s pill, known as molnupiravir. The company reported in September that its drug cut rates of hospitalization and death by 50%. Experts warned against comparing preliminary results because of differences in the studies, including where they were conducted and what types of variants were circulating.

“It’s too early to say who won the hundred meter dash,” Mellors said. “There’s a big difference between 50% and 90% but we need to make sure the populations were comparable.”

Although Merck's pill is further along in the U.S. regulatory process, Pfizer's drug could benefit from a safety profile that is more familiar to regulators with fewer red flags. While pregnant women were excluded from the Merck trial due to a potential risk of birth defects, Pfizer’s drug did not have any similar restrictions. The Merck drug works by interfering with the coronavirus' genetic code, a novel approach to disrupting the virus.

Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.

The drug was first identified during the SARS outbreak originating in Asia during 2003. Last year, company researchers decided to revive the medication and study it for COVID-19, given the similarities between the two coronaviruses.

The U.S. has approved one other antiviral drug for COVID-19, remdesivir, and authorized three antibody therapies that help the immune system fight the virus. But they have to be given by IV or injection at hospitals or clinics, and limited supplies were strained by the last surge of the delta variant.

Shares in New York-based Pfizer Inc. gained 11% to close at $48.61 on Friday.


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

  • Associated Categories: Associated Press (AP), AP National News, AP Online National News, Top General short headlines, AP Health, AP Business, AP Business - Industries, AP Business - Health Care
© Copyright 2022
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Pfizer says COVID-19 pill cut hospital, death risk by 90%
Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections
7:26AM ( 12 minutes ago )
The Latest: Shipping firms seek technology to cut emissions
Major shipping companies are calling for governments to put more money into researching and developing cleaner technologies to help the industry reduce its greenhouse gas emissions
7:21AM ( 18 minutes ago )
Qatari club agrees to let Xavi become Barcelona coach
Xavi Hernández will be allowed to become Barcelona’s next coach upon the payment of his release clause from Qatari club Al-Sadd
7:08AM ( 31 minutes ago )
Associated Press (AP)
Biden's big bill on brink of House votes, but fights remain
Democrats in the House appear on the verge of advancing President Joe Biden’s $1.85 trillion-and-growing domestic policy package
5:42AM ( 1 hour ago )
China LGBT rights group shuts down amid hostile environment
An influential LGBT advocacy group in China that has spearheaded many of the legal cases pushing for greater rights is halting its work amid growing restrictions on social activism
4:52AM ( 2 hours ago )
Bosnian doctors brace for new wave as virus rages in region
Doctors in Bosnia are bracing for a new wave of the coronavirus in the Balkan nation, which has a low vaccination rate and has been among the hardest hit countries in Europe earlier in the pandemic
4:41AM ( 2 hours ago )
AP National News
Taylor, ground game help Colts find easy path past Jets
Carson Wentz threw three touchdown passes and Jonathan Taylor rushed for 172 yards and two scores as Indianapolis beat the New York Jets 45-30
12:14AM ( 7 hours ago )
October jobs report is expected to show a pickup in hiring
After two disappointing months of hiring, a key question overhanging Friday’s U.S. jobs report for October will be whether companies found more success this time in filling millions of open positions
12:01AM ( 7 hours ago )
2 dead in dramatic shootout near upscale Mexican resorts
A commando of masked drug gang gunmen stormed ashore at a beach on Mexico’s Caribbean coast in front of luxury hotels and executed two drug dealers from a rival gang
11:37PM ( 8 hours ago )
AP Online National News
World shares, Wall St futures lower ahead of US jobs report
Shares have opened lower in Europe after a downbeat day in Asia, where Chinese benchmarks sagged under revived concerns over property developers
4:35AM ( 3 hours ago )
Dutch Supreme Court to rule in $50 billion Yukos case
The Dutch Supreme Court is set to rule in a $50 billion legal battle between Russia and former shareholders of the country’s bankrupted oil giant Yukos
4:26AM ( 3 hours ago )
Honda lowers profit, vehicle sales forecast over chip crunch
Japanese automaker Honda has lowered its profit and vehicle sales forecasts for the fiscal year, pointing to a supply crunch in chips and rising material costs
3:54AM ( 3 hours ago )
AP Business
Supply chain delays disrupt California agriculture exports
California farmers say they are having trouble exporting their crops because of delays in the global supply chain
7:30PM ( 12 hours ago )
Black trainer taking aim at Breeders' Cup with modest filly
California Angel has already beaten the odds before she even runs in the Breeders’ Cup
7:09PM ( 12 hours ago )
US government works to 'cocoon' old nuclear reactors
Costs to clean up a massive nuclear weapons complex in Washington state are usually expressed in the hundreds of billions of dollars and involve decades of work
6:49PM ( 12 hours ago )
AP Business - Industries
AstraZeneca pulls request for Swiss approval of COVID shot
AstraZeneca says it is withdrawing its application for approval of its COVID-19 vaccine in Switzerland because the country’s medical regulator wanted to restrict its use to people over age 50
9:24AM ( 22 hours ago )
UK authorizes Merck antiviral pill, 1st shown to treat COVID
Britain has granted a conditional authorization to Merck’s coronavirus antiviral
8:54AM ( 22 hours ago )
Moderna lowers forecast for 2021 COVID-19 vaccine deliveries
Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year
8:11AM ( 23 hours ago )
AP Business - Health Care
Qatari club agrees to let Xavi become Barcelona coach
Xavi Hernández will be allowed to become Barcelona’s next coach upon the payment of his release clause from Qatari club Al-Sadd
7:08AM ( 33 minutes ago )
New COVID-19 pill cut hospital, death risk by 90%
Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections
6:50AM ( 50 minutes ago )
Lone French fisherman left adrift in UK-France fishing spat
French fisherman Hermann Outrequin gave up his fishing company job and went independent in 2019 to have more time for his newborn son
6:42AM ( 59 minutes ago )
China lashes out at press freedom survey in Hong Kong
China has criticized a press freedom survey from the Hong Kong Foreign Correspondents’ Club that found nearly half its members are considering leaving the city
6:34AM ( 1 hour ago )